Reviews/SGLT2 Inhibitors/SGLT2 inhibitors reduce MACE in T2D with established cardiovascular disease
· SG-CV-01 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
Every primary study the panel could use points the same way: people with type 2 diabetes who took an SGLT inhibitor had fewer major heart events. The one randomised trial showed a clear reduction [2], and two real-world studies in patients with coronary or atherosclerotic disease agreed [8], [11]. The catch is that the trial tested sotagliflozin, an atypical drug that blocks both SGLT1 and SGLT2, in a kidney-disease population rather than the exact class and patients the claim names. The remaining on-class support comes from observational data, which cannot rule out that other differences between patients drove the result. The well-known placebo-controlled trials of pure SGLT2 inhibitors are mentioned only inside review articles here, so they could not be used as direct evidence. The panel therefore found the claim supported and consistent, but not firmly nailed down.
The included primary studies are uniform in direction: SGLT inhibition is associated with lower MACE. The randomised trial [2] reports total MACE HR 0.77 (95% CI 0.65-0.91; p=0.0020), with parallel reductions in myocardial infarction (HR 0.68) and stroke (HR 0.66). Observational cohort [8] found MACE of 10.8% versus 22.1% in SGLT2-inhibitor users versus non-users with non-obstructive coronary disease, and population study [11] found reduced MACE with SGLT2 inhibitors versus GLP-1 receptor agonists in men (sHR 0.78) and in women with ASCVD (sHR 0.36). The consistency spans different drugs, designs and settings, which is the chain's main strength [2], [8], [11]. The contested point: The division is whether this corpus supports the exact class-and-population claim or only a near neighbour. The sole RCT [2] uses a dual SGLT1/2 inhibitor in a CKD-defined cohort where only 48.6% had a cardiovascular-disease history, so it is indirect on both the drug class and the 'established cardiovascular disease' population, leaving the directly on-class evidence observational [8], [11].
All 18 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from SGLT2 Inhibitors, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The sole RCT [2] tests sotagliflozin, a dual SGLT1/2 inhibitor whose ischaemic MACE benefit the authors state 'has not been previously observed with other SGLT inhibitors'; it cannot represent the SGLT2i class on MACE.
SCORED [2] enrolled T2D + CKD + CV risk, with only 48.6% having a CVD history, so roughly half the population lacked the 'established cardiovascular disease' the claim specifies.
Where it remains uncertain. The one RCT tests an atypical dual SGLT1/2 inhibitor in a CKD population with only 48.6% having prior CVD [2], so the on-class, established-CVD claim rests on observational data [8], [11].
Aleatory
MACE counts in [8] (12 vs 57 of 369) and the subgroup estimates in [11] rest on few events, so chance variation around the point estimates is substantial.
Epistemic
The on-class signal ([8], [11]) comes from non-randomised comparisons where unmeasured prescribing and patient differences could drive the association.
Inferential
The only RCT [2] tests a dual SGLT1/2 inhibitor whose ischaemic benefit the authors say is not previously seen with other SGLT inhibitors, so inferring the pure SGLT2i class is a leap.
The load-bearing papers from a corpus of 18, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Only randomised, placebo-controlled MACE result in the included set; a significant reduction, but with a dual SGLT1/2 inhibitor in a T2D + CKD population.
“Patients in the sotagliflozin group had a significantly lower rate of total MACE than those in the placebo group (4·8 events per 100 person-years vs 6·3 events per 100 person-years; hazard ratio [HR] 0·77 [95% CI 0·65-0·91]; p=0·0020).”
Panel auditInternal validity: high · scope of inference: Dual SGLT1/2 inhibition and ischaemic MACE in T2D with CKD and additional CV risk.Key limitations: dual SGLT1/2 inhibitor not pure SGLT2 · CKD-defined population not established CVD · trial ended early
Observational SGLT2i-specific MACE reduction in T2D with ischaemic (non-obstructive) coronary disease; confounding-prone, narrow population.
“At the follow-up end, SGLT2-I users vs. Non-SGLT2-I users had a lower rate of MACEs [n 12 (10.8%) vs. n 57 (22.1%); p < 0.05].”
Panel auditInternal validity: low · scope of inference: MACE over one year in T2D patients with multivessel non-obstructive coronary stenosis treated or not with SGLT2i after PCI.Key limitations: observational non-randomized · confounding by indication · single composite over short follow-up
Population-cohort MACE reduction with SGLT2i, including women with ASCVD (sHR 0.36); active GLP-1RA comparator means relative rather than placebo-referenced effect.
“SGLT2i (n = 4231), compared to GLP-1RAs (n = 3795), reduced MACE rates in men (sHR 0.78; 95%CI 0.66-0.93), but not women.”
Panel auditInternal validity: low · scope of inference: Relative MACE rates of SGLT2i versus GLP-1RA by sex and CVD status in Australian T2D patients.Key limitations: active comparator not placebo · observational · subgroup-level findings
The comparison shows combination versus SGLT2i monotherapy and cannot establish whether SGLT2i reduce MACE relative to no SGLT2i treatment.
Panel auditInternal validity: low · scope of inference: Whether adding a second agent to SGLT2i or GLP-1RA lowers MACE after AMI in T2D.Key limitations: no untreated comparator · observational · SGLT2i effect not isolated
4 of 18 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent direction plus one positive RCT warrants Likely, but the drug/population indirectness and reliance on observational on-class evidence keep it below Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No primary pure-SGLT2i outcome trial in this corpus. The claim is about the SGLT2i class, but the only RCT [2] is a dual SGLT1/2 inhibitor and the pure-class trials appear only inside excluded reviews. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Include the placebo-controlled pure-SGLT2i cardiovascular outcome trials as primary data and read MACE in the established-CVD stratum directly.
Open question: Does a pure SGLT2 inhibitor, versus placebo, reduce MACE specifically in T2D patients with established cardiovascular disease? Why it is still open: The only RCT in the corpus [2] tests a dual SGLT1/2 inhibitor in a CKD cohort, and the pure-class outcome trials are absent as primary data.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 23 Oct 2026 · protocol v0.19